IGC Pharma, Inc. Finite-Lived Intangible Assets, Net
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsNet · last filed 2026-08-14
- 2026-06-30: Finite-Lived Intangible Assets, Net $413.00K.
- 2026-03-31: Finite-Lived Intangible Assets, Net $427.00K.
- 2025-12-31: Finite-Lived Intangible Assets, Net $441.00K.
- 2025-09-30: Finite-Lived Intangible Assets, Net $334.00K.
| Period end | Finite-Lived Intangible Assets, Net |
|---|---|
| 2026-06-30 | $413.00K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $427.00K 10-Q · filed 2026-05-15 |
| 2025-12-31 | $441.00K 10-Q · filed 2026-08-14 |
| 2025-09-30 | $334.00K 10-Q · filed 2025-11-14 |
| 2025-06-30 | $345.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $359.00K 10-KT · filed 2026-03-18 |
| 2024-12-31 | $571.00K 10-Q · filed 2025-02-14 |
| 2024-09-30 | $577.00K 10-Q · filed 2024-11-12 |
| 2024-06-30 | $672.00K 10-Q · filed 2024-08-07 |
| 2024-03-31 | $689.00K 10-K · filed 2025-06-27 |
| 2023-12-31 | $607.00K 10-Q · filed 2024-02-14 |
| 2023-09-30 | $620.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $630.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $636.00K 10-K · filed 2024-06-24 |
| 2022-12-31 | $546.00K 10-Q · filed 2023-02-14 |
| 2022-09-30 | $529.00K 10-Q · filed 2022-11-01 |
| 2022-06-30 | $493.00K 10-Q · filed 2022-08-05 |
| 2022-03-31 | $271.00K 10-K · filed 2023-07-07 |
| 2021-12-31 | $274.00K 10-Q · filed 2022-02-10 |
| 2021-09-30 | $272.00K 10-Q · filed 2021-10-29 |
| 2021-06-30 | $221.00K 10-Q · filed 2021-08-11 |
| 2021-03-31 | $226.00K 10-K · filed 2022-06-23 |
| 2020-12-31 | $156.00K 10-Q · filed 2021-02-16 |
| 2020-09-30 | $155.00K 10-Q · filed 2020-11-20 |
| 2020-06-30 | $132.00K 10-Q · filed 2020-08-19 |
| 2020-03-31 | $135.00K 10-K · filed 2021-06-14 |
| 2019-03-31 | $0.00 10-K · filed 2020-07-13 |